---
title: Locke Msci
draft: true
---

## Summary
- Building a Better Cohort of Patients with Hypercapnic Respiratory Failure
- Overview
- What is Hypercapnic Respiratory Failure?
- Hypercapnia is common‚Ä¶
- Age
- Hypercapnia is associated with high - and likely increasing - morbidity, mortality, and cost
- Patients with hypercapnia are identified unreliably and late in their illness
- Hypothesis: We Can Identify Them & It Would Help?
- Evidence Islands
- Recognized Hypercapnia
- All Hypercapnia
- Disease Paradigm Doesn‚Äôt Mirror Practice

## Slide outline
### Slide 1
- Building a Better Cohort of Patients with Hypercapnic Respiratory Failure
- Brian Locke, MD
- T32 Fellow. Division of Pulmonary, Critical Care, and Occupational Pulmonary Medicine
- Wayne Richards MS, Joseph Finkelstein MD PhD MA, Jeanette Brown MD PhD, Ramkiran Gouripeddi MBBS MS, Krishna M Sundar MDDepartments of Internal Medicine and Biomedical Informatics
- This research was supported by the National Institutes of Health under Ruth L. Kirschstein National Research Service Award 5T32HL105321 and the American Thoracic Society Academic Sleep and Pulmonary Integrated Research/Clinical Fellowship (ASPIRE) Program
### Slide 2
- Overview
- 10 slides on the problem
- 10 slides on what we‚Äôve done
- 10 slides on what we plan to do
### Slide 3
- What is Hypercapnic Respiratory Failure?
- ùê¥ùëüùë°ùëíùëüùëñùëéùëô ùê∂ùëÇ2 ‚àùùëáùëñùë†ùë†ùë¢ùëí ùëÉùëüùëúùëëùë¢ùëêùë°ùëñùëúùëõ ùëúùëì ùê∂ùëÇ2ùëáùëúùë°ùëéùëô ùëâùëíùëõùë°ùëñùëôùëéùë°ùëñùëúùëõ ‚àíùëäùëéùë†ùë°ùëíùëë ùëâùëíùëõùë°ùëñùëôùëéùë°ùëñùëúùëõ
- Diseases that cause hypercapnia (‚Üë Arterial CO2)
- ‚Üë Requirement
- ‚Üì Capacity
- ‚Üì Drive
- COPD (inefficient ventilation)
- Obesity (more CO2 production)
- Neuro-musc. disease
- COPD
- Obesity
- Opiates
- Metabolic Alkalosis
### Slide 4
- Hypercapnia is common‚Ä¶
- Common contributors to Hypercapnic Respiratory Failure:
- Advanced Age
- Opiate Use
- Obesity
- Advanced Lung Dz
- Multimorbidity
- Population-standardized prevalence PaCO2 > 45 mmHg after excluding iatrogenic causes:
- 150 per 100,000 person/year
- Only inpatients, only those with blood gasses checked
- Comparison: Decompensated Cirrhosis 94.9 (US, 2017) per 100,000 person-year
### Slide 5
- Age
- Group
- Prevalence
- Per 100,000 p.yr.
- 15-24
- 14 (9-22)
- 25-34
- 29 (22-39)
- 35-44
- 42 (33-54)
- 45-54
- 80 (66-96)
- 55-64
- 196 (71-225)
- 65-74
- 517 (463-577)
- 75-84
- 1160 (1046-1286)
- 85+
- 1712 (1481-1980)
### Slide 6
- Hypercapnia is associated with high - and likely increasing - morbidity, mortality, and cost
- Inpatient ICD code for Hypercapnic Respiratory Failure
- 23% 30d readmission rate
- Same as CHF, more than MI
- 66% with recurrence
- Decompensated Cirrhosis, for reference
### Slide 7
- Patients with hypercapnia are identified unreliably and late in their illness
- Published 2003; 3 hospitals, Denver
- ABG on all inpatients BMI 35+
- 31% with unrecognized with hypercapnia
### Slide 8
- Hypothesis: We Can Identify Them & It Would Help?
### Slide 9
- Evidence Islands
- Severe COPD
- Obesity Hypovent
- ALS
- COPD: PaCO2 > 52 mmHg when stable, OSA noncontributory
- OHS: PaCO2 > 45 mmHg; No obstruction, AM Co2 up by 7 or PSG
- Restrictive (including NMD) ABG 45>, or FVC < 50% or low muscle strength.
### Slide 10
- Recognized Hypercapnia
- All Recognized Cases
- (Multifactorial Causes,
- Relapsing-Recurrent)
- What portion have applicable evidence-based management?
- What portion of patients with hypercapnic respiratory failure qualify for NIV?
- Does treatment help the others?
- ???
- Severe COPD
- Obesity Hypovent
- ALS
### Slide 11
- All Hypercapnia
- All Recognized Cases
- (Multifactorial Causes,
- Relapsing-Recurrent)
- ???
- What portion of patients are missed?
- Are the patients who are missed consequential?
- Severe COPD
- Obesity Hypovent
- ALS
- All Cases
### Slide 12
- Disease Paradigm Doesn‚Äôt Mirror Practice
- Disease-based
- Syndrome-based
- Understand the physiology
- Mirrors Diagnostic Order (‚ÜëCO2 often recognized first)
- Homogenous Sample for Clinical trials
- Different Causes Managed Similarly
- Quality Improvement (Presentation ‚Üí Treatment)
### Slide 13
- Non-invasive ventilation is not the only option
- Obesity and OSA are contributors to many cases
- MDCRC 6200 Systematic Review and Meta-analysis
- All RCTs: Pharmacologic and Surgical Weight Loss
- Expected effect of Tirzepatide: AHI -13.3 events/hr [-8.9 to -17.7]; 44% improvement.
- Decrease of 0.45 (95% CI: 0.18-0.73 events/hour) events per hour for each 1% body weight loss
- The Association of Weight Loss from Antiobesity Medications or Bariatric Surgery and Apnea-Hypopnea Index in Obstructive Sleep Apnea: A Systematic Review and Meta-Regression. Brian W. Locke MD; Ainhoa Gomez Lumbreras MD, PhD; Chia Jie Tan PhD; Teerawat Nonthasawadsri PharmD; Sajesh Veettil MSPharm, PhD; Chanthawat Patikorn PharmD; Nathorn Chaiyakaunapruk PharmD, PhD
### Slide 14
- Impact of Doing this Research
- Patients with hypercapnic respiratory failure are not well served by our scientific knowledge base
- Identified cases are at high risk, but often we don‚Äôt know what to do
- We unreliably diagnose hypercapnia (even when best management practices known)
- Better identification of patients with hypercapnia will allow:
- Improved care for patients with understood best management
- Improve the rigor of research on multifactorial hypercapnia
- Allow for hypercapnic respiratory failure as a study outcome
- Benchmark current health system performance at diagnosis and treatment
### Slide 15
- Approach to the Solution
- Hypothesis: Health Record Data contains enough information to helpfully stratify patients with hypercapnic respiratory failure.
- Consider:
- Example OSA
- STOP BANG
- Subjective measures:
- Loud snoring, tired/fatigued/sleepy, observed apneas? Report of HTN
- Objective measures:
- BMI, Age, Neck Circumference, Gender
- High-risk increased perioperative complications
### Slide 16
- Pulse Oximeter vs ???? For CO2.
- Hypoxemic (Low O2) Respiratory Failure
- Hypercapnic (High CO2) Respiratory Failure
- Low arterial blood oxygen tension
- High arterial blood carbon dioxide tension
- Definitive diagnosis by Arterial Blood Gas
- Reliably Identified by Pulse Oximetry
- Limited non-invasive testing
- Immediate Life Threat if Severe
- Indicates potentially treatable excess risk
- Applied widely since 1980s with improved recognition
- No systematic Identification
### Slide 17
- Role of HCO3- in Diagnosis of Hypercapnia
- ùêª2ùëÇ+ùê∂ùëÇ2 ‚áãùêª2ùê∂ùëÇ3 ‚áã H+ + HCO3-
- Boston Acid-Base ‚ÄúRules‚Äù:
- Acute: ‚Üë CO2 by 10 mmHg ‚Üë HCO3- by 1 mEq/L
- Chronic: ‚Üë CO2 by 10 mmHg ‚Üë HCO3- by 4 mEq/L
- Thus,
- If CO2 has been ‚Üë enough, for long enough, and kidneys work well enough: cases of hypercapnia will have ‚Üë HCO3-
- If there is no other cause of metabolic alkalosis, non-cases will not have ‚Üë HCO3-
### Slide 18
- Does HCO3- work in other situations?
- Target population: patients whom a clinicians should consider hypercapnia
- Spectrum bias/effect
- Data source: all encounters in TriNetX research network during 2022 who met:
- Predisposing condition: COPD, CHF, Obesity‚Ä¶
- Diagnostic Testing Sent: VBG, ABG
- Related Diagnosis: Other Resp Failure
- Related Management: Vent. Support
- Inpatient, Outpatient, Emergency Visits
- De-identified, patient-level data
- Federated Health Record Data
- 80 US Healthcare Orgs (mostly AMCs)
- Allegedly, Reconciled Inter-institution Linkage
- NOT able to identify institution
### Slide 19
- Add slide with what Wayne did
### Slide 20
- Data Cleaning
- Types of Missing Data:
- For a given encounter, the institution must have submitted some data (any data) for each of the data elements requested.
- Data validation measures:
- Positive controls: if paralytic, expect intubation
- Negative controls: <BMI 30 in OHS
- True (patho)physiologic state
- What the clinician recognizes
- What the clinician documents
- What information is structured
- What data is aggregated in TriNetX
- Problem for our study
- Missing data here is part of what we want to study
### Slide 21
- Results:
- Total
- No ABG Obtained
- ABG Obtained
- N879,019
- N675,620
- N203,399
- Encounter Characteristics
- Ambulatory
- 39% (343,699)
- 50% (334,457)
- 5% (9,242)
- Emergency
- 20% (175,792)
- 22% (146,066)
- 15% (29,726)
- Inpatient
- 41% (359,528)
- 29% (195,097)
- 81% (164,431)
- Critical Care Services Billed
- 13% (111,320)
- 6% (41,976)
- 34% (69,344)
- Patient Characteristics
- Age (years)
- 58 (¬±18)
- 57 (¬±18)
- 61 (¬±17)
- Female
- 53% (465,854)
- 55% (373,158)
- 46% (92,696)
- BMI kg/m2
- 34 (¬±9)
- 35 (¬±9)
- 29 (¬±7)
- CHF
- 17% (145,615)
- 16% (106,492)
- 19% (39,123)
- CKD
- 15% (128,047)
- 14% (94,048)
- 17% (33,999)
- COPD
- 16% (144,127)
- 16% (106,788)
- 18% (37,339)
- Neuromuscular Disease
- 4% (35,539)
- 4% (27,725)
- 4% (7,814)
- OSA
- 21% (188,757)
- 24% (160,082)
- 14% (28,675)
- Diuretics (outpatient)
- 38% (334,400)
- 38% (256,188)
- 38% (78,212)
- Opiate (outpatient)
- 59% (518,493)
- 57% (387,725)
- 64% (130,768)
- Serum Bicarbonate (mEq/L)
- 24.6 (¬±4.7)
- 25.0 (¬±4.1)
- 23.6 (¬±5.7)
- Outcomes
- Non-invasive Ventilation?
- 4% (32,542)
- 2% (15,352)
- 8% (17,190)
- Invasive Mechanical Ventilation
- 6% (52,533)
- 1% (10,054)
- 21% (42,479)
- CO2 > 45 mmHg?
- 32% (64,544)
### Slide 22
- Statistical Analyses:
- Receiver Operating Characteristic (ROC) Curve Analysis
- ROC-Generalized Linear Modeling
- Interval Likelihood Ratios (iLR)
- How well does HCO3- separate patients with ‚ÜëCO2 from those without (discrimination)?
- What characteristics independently associate with better or worse discrimination?
- How much does a particular HCO3- value change the likelihood of ‚ÜëCO2 being present?
- (Exposure) HCO3- and (Outcome) ABG obtained on 1st day of encounter.
### Slide 23
- Results:
### Slide 24
- Results:
### Slide 25
- Results:
### Slide 26
- Additional hypothesis: Potassium levels will improve accuracy.
- Rationale:
- False positives are caused by metabolic alkaloses
- Most metabolic alkaloses cause hypokalemia (diuretics, vomiting, hypovol.)
- Therefore, high bicarbonate with normal/high potassium is more likely a true positive
### Slide 27
- Results:
### Slide 28
- Conclusions
- Serum bicarbonate is potentially diagnostically useful in a variety of previously unvalidated situations
- Some factors correlate with better performance (e.g. Loop diuretic, COPD, CHF, female sex, older age) and others with worse (ER, CKD, Opiate use)
- Loop diuretic performance contradicts prior hypothesis: while they increase false positives, they decrease false negatives more.
- New Finding: Potassium levels and bicarbonate together provide stronger evidence for or against hypercapnia being present.
### Slide 29
- Limitations:
- Partial verification: not everyone gets an arterial blood gas to verify if they have hypercapnia or not.
- Current Finding applies to type of patients who get ABGs
- Probability of obtaining an ABG is variable and idiosyncratic
- Inverse probability of blood-gas weighting? Missing data is tricky
- ‚ÄòAcute‚Äô, transient hypercapnia will be under-identified.
- Will miss if inadequate time for kidneys to retain HCO3-
- Calendar-day time matching
- Is this a bad thing?
- Is the data quality sufficient?
- Restricted analyses to single-encounter data (cross-sectional)
### Slide 30
- Future: More Predictors Better?
- Traditional clinical test evaluation ‚Üí bioinformatics
- (priority from easy to understand ‚Üí works better)
- Approach: Cross-validation
- Bias
- Variance
- Miss the signal (underfitting)
- Fitting the noise(overfitting)
- Too far in either direction worse performance with new data.
### Slide 31
- Approach:
- Same Dataset
- Take structured data elements that are immediately available in HER
- Age, Sex, Serum HCO3- , Serum K+, Serum Creatinine, BMI, Hgb, Venous BG
- Modeling approach: Logistic regression with restricted cubic splines
- Random-forest decision trees: more flexible, less interpretable.
- Output: Predicted (log-odds) of Hypercapnia
### Slide 32
- Preliminary Results
- TBD
### Slide 33
- How can this be put to clinical use?
- Computable Phenotype: algorithms that use more information to label whether a patient has a disease.
- How you decide who ‚Äùcounts‚Äù as having hypercapnic respiratory failure influences the types of patients included..
- Inaccurate disease status classification is a problem for existing EHR-based research
- Use for: Exposure, Covariable Adjustment, Outcomes
### Slide 34
- Probabilistic Modeling Likelihood of Hypercapnia
- Validation & Tuning
- Aim 1: Add Unstructured Data
- Aim 2: Prospective Validation of PPV
- Aim 3: Evaluation of Prognostic Significance
- K23:5-yr
- Refinement and Validation of a method for constructing cohorts of patients with hypercapnia ‚Äì robust to variable diagnostic performance.
### Slide 35
- Aim 1: Incorporate Unstructured Data
- Natural Language Processing, Large Language Models
- BioBERT: LLM (like ChatGPT) pre-trained on medical text (PubMed/PMC)
- Train to recognize hypercapnia predictors using MIMIC4: 65,000 ICU admissions MGH/BWH
- Nursing triage assessments, Chest XR
- Apply with model to retrospective data from the University of Utah.
- Reference standard: patients who had arterial blood gasses obtained.
- Adjust model weights
- Generate measures of model performance (discrimination and calibration) to inform other aims
- OSA
- Pulmonary Embolism
- STOP BANG
- WELLS Score
- Subjective measures:
- Loud snoring, tired/fatigued/sleepy, observed apneas? Report of HTN
- Objective measures:
- BMI, Age, Neck Circumference, Gender
- Signs/Symptoms of DVT
- PE is most likely
- HR over 100
- Immobilized/Surgery w/n 4 weeks
- Prior PE,
- Hemoptysis
- Malignancy
- High-risk increased perioperative complications
- 0-1 points <1.2% prevalence
- 2-3 points 16.2% prevalence
- 4+ points 37.5% prevalence
- Prior efforts use data points you can‚Äôt get from structured fields
- (can only take specific values)
- 1990: Run a big enough prospective study and ask everyone
- 2023: Get ChatGPT to do it from what people document
### Slide 36
- Aim 2: Prospectively Validate: UUH Inpatients
- Deferred consent (CO2 Narcosis)
- Verify Positive Predictive Value (precision) in predicted high-risk patients with Transcutaneous CO2
- Smaller sample stratified sampling of the whole population.
- Prioritizes proof of concept, rather than delineate scope of the problem (initially)
- Sample Size Calculation: stata diagsampsi
- Rate of presentation to hospital: (TriNetX)
- % Predicted High Risk: (10%)
- % of eligible enrolled
- 25% ‚Äòprevalence‚Äô (Nowbar); model AUC; Se/Sp TcCO2 for true reference standard 85%/85%
### Slide 37
- Prior work:
- ‚Ä¶
- 49: Correct 93%, Wrong 7%: weight: 1.98%
- 48: Correct 88%, Wrong 12%: weight: 2.39%
- 47: Correct 80%, Wrong 20%: weight: 2.47%
- 46: Correct 69%, Wrong 31%: weight: 2.92%
- 45: Correct 57%, Wrong 43%: weight: 3.11%
- SENSITIVITY
- SPECIFICITY
- 44: Correct 57%, Wrong 43% 3.56%
- 43: Correct 69%, Wrong 31% weight 3.73
- 42: Correct 80%, Wrong 20% weight 4.16%
- 41: Correct 88%, Wrong 12% weight 4.25%
- 40: Correct 93%, Wrong 7% weight 4.58%
- ‚Ä¶.
- Expected test characteristics:
- sensitivity 89%
- specificity 92%
- if
- agreement ~6 mmHg
- same distribution of CO2
- Tool
- Health Record-Based Modeling
- Transcutaneous CO2
- Purpose
- Refine Estimation of Pre-test Odds of Hypercapnia
- Allow non-invasive CO2 assessment (patients unlikely to consent for research ABGs)
- Limitation
- Approach only externally validated in outpatient OHS assessment
- Prior 95% agreement +/- 6 mmHg insufficient for unstratified clinical use
### Slide 38
- Aim 3: Estimate the potential impact
- Overdiagnosis: people who meet the definition of disease, but do not benefit from it
- PaCO2 is an imperfect reference standard for what we care about: future harm
- Possible ‚Äì though not likely ‚Äì clinicians already identify the important cases
- Need a ‚Äòloyalty cohort‚Äô: patients whose rehospitalizations would be captured.
- Veterans Affairs ‚Äì or artificially constructed one from another data source.
- Hypothesis: Patients predicted to have had hypercapnia that was not recognized have a similar or excess risk of subsequent readmission as those identified (by blood gas and/or ICD code)
- Prior efforts use data points you can‚Äôt get from structured fields
- (can only take specific values)
### Slide 39
- OVERALL: Patients with Consequentially Missed Hypercapnia can be Identified Using Health Record Elements
- OVERALL: There is a significant burden of unrecognized hypercapnia among hospitalized patients.
- 3 aims
- Aim 1: Model Refinement and Local Optimization
- Aim 2: Prospective Validation
- Aim 3: Assess Potential Impact
- Hypothesis
- Fine-tuning and refining previously derived model will improve local performance
- Patients with hypercapnia that are not recognized are common can be identified using health record elements with high positive-predictive value.
- Inpatients who were predicted, but not confirmed, to have hypercapnic respiratory failure are at high risk of adverse outcomes.
- Rationale
- The model should be optimized for local performance
- Must be verified that model identifies unrecognized hypercapnia
- Need to confirm that the identified patients face elevated risk (ABG PaCO2 is an imperfect reference standard).
- Approach
- Optimizing model performance +/- use of NLP tools) applied to U of U data
- Non-invasively sample (with TcCO2) patients predicted to have hypercapnia that teams have not recognized
- Among patients with an admission for hypercapnia that is identified, how many had preceding admissions likely to have hypercapnia?
- Design
- Retrospective, U of U
- Prospective, U of U
- Retrospective, VA
- Payoff: This work will evaluate the potential for improved recognition of hypercapnia to help a particularly high-risk, enlarging, and understudied group of patients.
- Career Development: Prospective validations of bioinformatic tools require a unique skillset
### Slide 40
- Summary
- Considering hypercapnic respiratory failure as a syndrome offers insight into its attributable health burden
- Current diagnosis is haphazard and suboptimal
- This introduces problems for patient care and reliable research.
- Better use of health record data can help address both problems.
- Preliminary work has led to new clinical features, but more sophisiticated modeling is needed for impact.
- Related Questions
- Methods of handling of partial verification
- Regression-based vs Random Forest (or other ML)
- Clinical and modeling Incorporation of Venous BG
- Socio-technical barriers to diagnosis
- Longitudinal Cohort Creation
- Is UT atypical? (elevation)
- Sources of provider/unit/institution variation?
- Brian.Locke@hsc.utah.edu
### Slide 41
- TODO: No text extracted from this slide.


## Learning objectives
- Building a Better Cohort of Patients with Hypercapnic Respiratory Failure
- Overview
- What is Hypercapnic Respiratory Failure?
- Hypercapnia is common‚Ä¶
- Age

## Bottom line / summary
- Building a Better Cohort of Patients with Hypercapnic Respiratory Failure
- Overview
- What is Hypercapnic Respiratory Failure?
- Hypercapnia is common‚Ä¶
- Age

## Approach
1. TODO: Outline the initial assessment or decision point.
2. TODO: Outline the next diagnostic or management step.
3. TODO: Outline follow-up or escalation criteria.

## Red flags / when to escalate
- TODO: List red flags that require urgent escalation.

## Common pitfalls
- TODO: Capture common errors or missed steps.

## References
TODO: Add landmark references or guideline citations.

## Slides and assets
- [Presentations/2023-11-23 Locke MSCI.pptx](../../archive/Presentations/2023-11-23%20Locke%20MSCI.pptx)
- [Presentations/2023-12-8 Locke MSCI.pptx](../../archive/Presentations/2023-12-8%20Locke%20MSCI.pptx)

## Source materials
- [Presentations/2023-11-23 Locke MSCI.pptx](../../archive/Presentations/2023-11-23%20Locke%20MSCI.pptx)
- [Presentations/2023-12-8 Locke MSCI.pptx](../../archive/Presentations/2023-12-8%20Locke%20MSCI.pptx)
